JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.63 1.24

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.63

Max

1.65

Põhinäitajad
By Trading Economics
Sissetulek	-2.8M -16M
Müük	-8.7M 5.5M
Kasumimarginaal	-282.723
Töötajad	81
EBITDA	-4.2M -15M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+134.97% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	64M 716M
Eelmine avamishind	0.39
Eelmine sulgemishind	1.63

Uudiste sentiment

By Acuity

45%

55%

143 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. mai 2026, 21:36 UTC

Omandamised, ülevõtmised, äriostud

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1. mai 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1. mai 2026, 18:37 UTC

Suurimad hinnamuutused turgudel

Senseonic Shares Slide on Underwritten Offering Price

1. mai 2026, 16:46 UTC

Suurimad hinnamuutused turgudel

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2. mai 2026, 19:57 UTC

Omandamised, ülevõtmised, äriostud

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2. mai 2026, 15:24 UTC

Tulu

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2. mai 2026, 12:46 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2. mai 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

1. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. mai 2026, 20:42 UTC

Tulu

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1. mai 2026, 19:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. mai 2026, 19:33 UTC

Market Talk

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1. mai 2026, 19:18 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1. mai 2026, 19:13 UTC

Market Talk

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1. mai 2026, 18:36 UTC

Tulu

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1. mai 2026, 18:35 UTC

Tulu

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1. mai 2026, 18:28 UTC

Tulu

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1. mai 2026, 18:27 UTC

Market Talk

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1. mai 2026, 18:14 UTC

Omandamised, ülevõtmised, äriostud

Barclays Completes Acquisition of Best Egg

1. mai 2026, 18:04 UTC

Tulu

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1. mai 2026, 17:43 UTC

Market Talk

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1. mai 2026, 17:37 UTC

Market Talk

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1. mai 2026, 17:30 UTC

Market Talk

Tulu

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1. mai 2026, 17:28 UTC

Market Talk

Tulu

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1. mai 2026, 17:21 UTC

Market Talk

Tulu

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1. mai 2026, 17:19 UTC

Market Talk

Uudisväärsed sündmused

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1. mai 2026, 16:38 UTC

Market Talk

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1. mai 2026, 16:23 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

134.97% tõus

12 kuu keskmine prognoos

Keskmine 3.83 USD 134.97%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

143 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.